Globomycin derivative G2A

• UNSPSC Description:

  Globomycin derivative G2A (Compound G2A) is an inhibitor for lipoprotein signal peptidase II (LspA), with an IC50 of 604 nM. Globomycin derivative G2A inhibits E. coli, P. aeruginosa and A. baumannii, with MIC ranging from 12.5 to 32 μg/mL[1].

• Target Antigen:

  Bacterial

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/globomycin-derivative-g2a.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(CCNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N(C([C@@H]1C)=O)C)CC(C)C)=O)[C@@H](CC)C)=O)CO)=O)[C@@H](O)C)=O)N1CCCCCCCC

• Molecular Weight:

  682.89

• References & Citations:

  [1]Craven TW, et al., Computational Design of Cyclic Peptide Inhibitors of a Bacterial Membrane Lipoprotein Peptidase. ACS Chem Biol. 2024 May 17;19(5):1125-1130.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported